Grigory V. Volchenkov
14 Papers
25 Citations
Grigory V. Volchenkov is an academic researcher. The author has contributed to research in topics: Tuberculosis & Extensively drug-resistant tuberculosis. The author has an hindex of 11, co-authored 14 publications.
Chat about Author
Papers
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement
Christoph Lange,Ibrahim Abubakar,Jan-Willem C. Alffenaar,Graham H. Bothamley,Jose A. Caminero,Anna Cristina Calçada Carvalho,Kwok Chiu Chang,Luigi Codecasa,Ana Maria Correia,Valeriu Crudu,Peter Davies,Martin Dedicoat,Francis Drobniewski,Raquel Duarte,Cordula Ehlers,Connie Erkens,Delia Goletti,Gunar Günther,Elmira Ibraim,Beate Kampmann,Liga Kuksa,Wiel C M de Lange,Frank van Leth,Jan Van Lunzen,Alberto Matteelli,Dick Menzies,Ignacio Monedero,Elvira Richter,Sabine Rüsch-Gerdes,Andreas Sandgren,Anna Scardigli,Alena Skrahina,Enrico Tortoli,Grigory V. Volchenkov,Dirk Wagner,Marieke J. van der Werf,Bhanu Williams,Wing Wai Yew,Jean-Pierre Zellweger,Daniela Maria Cirillo +39 more
TL;DR: This document summarises the current knowledge on the prevention, diagnosis and treatment of adults and children with MDR/XDR-TB and their contacts, and provides expert consensus recommendations on questions where scientific evidence is still lacking.
324
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study
Tracy Dalton,Peter Cegielski,Somsak Akksilp,Luis Asencios,Janice Campos Caoili,Sang Nae Cho,Vladislav V. Erokhin,Julia Ershova,Ma Tarcela Gler,Boris Y. Kazennyy,Hee Jin Kim,Kai Kliiman,Ekaterina V. Kurbatova,Charlotte Kvasnovsky,Vaira Leimane,Martie van der Walt,Laura E. Via,Grigory V. Volchenkov,Martin A. Yagui,Hyungseok Kang +19 more
TL;DR: Previous treatment with second-line drugs was consistently the strongest risk factor for resistance to these drugs, which increased the risk of XDR tuberculosis by more than four times.
225
MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network.
Giovanni Battista Migliori,Simon Tiberi,Simon Tiberi,Alimuddin Zumla,Eskild Petersen,Jeremiah Chakaya,Jeremiah Chakaya,Christian Wejse,Marcela Muñoz Torrico,Raquel Duarte,Jan-Willem C. Alffenaar,Jan-Willem C. Alffenaar,Jan-Willem C. Alffenaar,H. Simon Schaaf,Ben J. Marais,Daniela Maria Cirillo,Riccardo Alagna,Adrian Rendon,Emanuele Pontali,Alberto Piubello,Jose Figueroa,Gabriella Ferlazzo,Alberto L. García-Basteiro,Alberto L. García-Basteiro,Rosella Centis,Dina Visca,Lia D'Ambrosio,Giovanni Sotgiu,T. Abu Arkub,Onno W. Akkerman,Alena Aleksa,Evgeny Belilovski,Enrique Bernal,F-X. Blanc,Martin J. Boeree,Sergey Borisov,Judith Bruchfeld,J. Cadiñanos Loidi,Jose A. Caminero,Anna Cristina Calçada Carvalho,J.J. Cebrian Gallardo,Charalampos,Edvardas Danila,L. Davies Forsman,Justin T Denholm,Keertan Dheda,Roland Diel,Saulius Diktanas,Claudia C. Dobler,Martin Enwerem,Susanna Esposito,N. Escobar Salinas,Alex Filippov,B. Formenti,J.M. García García,Delia Goletti,R. Gomez Rosso,Gina Gualano,Petros Isaakidis,Anna Kaluzhenina,S. Koirala,Liga Kuksa,Heinke Kunst,Yang Li,Cecile Magis-Escurra,Vinicio Manfrin,Selene Manga,Katerina Manika,Valentina Marchese,E. Martínez Robles,Andrey Maryandyshev,Alberto Matteelli,Alessandro Wasum Mariani,Jesica Mazza-Stalder,Fernanda Carvalho de Queiroz Mello,L. Mendoza,A. Mesi,Skaidrius Miliauskas,H. Mustafa Hamdan,Norbert Ndjeka,M. Nieto Marcos,Tom H. M. Ottenhoff,Domingo Palmero,Fabrizio Palmieri,Apostolos Papavasileiou,Marie-Christine Payen,Agostina Pontarelli,M. Pretti Dalcolmo,S. Quirós Fernandez,R. Romero,D. Rossato Silva,A.P. Santos,Barbara Seaworth,M. Sinitsyn,Alena Skrahina,Ivan Solovic,Antonio Spanevello,Marina Tadolini,C. Torres,Zarir F Udwadia,M. van den Boom,Grigory V. Volchenkov,Askar Yedilbayev,R. Zaleskis,Jean-Pierre Zellweger +104 more
TL;DR: The review comprehensively describes the latest information on contact tracing and LTBI management in MDR-TB contacts, while providing guidance on post-treatment functional evaluation and rehabilitation of TB sequelae, infection control and other public health priorities.
191
Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
Courtney M. Yuen,Ekaterina V. Kurbatova,Thelma E. Tupasi,Janice Campos Caoili,Martie van der Walt,Charlotte Kvasnovsky,Charlotte Kvasnovsky,Martin Yagui,Jaime Bayona,Carmen Contreras,Vaira Leimane,Julia Ershova,Laura E. Via,Hee Jin Kim,Somsak Akksilp,Boris Y. Kazennyy,Grigory V. Volchenkov,Ruwen Jou,Kai Kliiman,Olga V. Demikhova,Irina Vasilyeva,Tracy Dalton,J. Peter Cegielski +22 more
TL;DR: MDR TB regimens including more potentially effective drugs than the minimum of five currently recommended by WHO may encourage improved response to treatment in patients with MDR TB.
Additional Drug Resistance of Multidrug-Resistant Tuberculosis in Patients in 9 Countries
Ekaterina V. Kurbatova,Tracy Dalton,Julia Ershova,Thelma E. Tupasi,Janice Campos Caoili,Martie van der Walt,Charlotte Kvasnovsky,Martin Yagui,Jaime Bayona,Carmen Contreras,Vaira Leimane,Laura E. Via,Hee Jin Kim,Somsak Akksilp,Boris Y. Kazennyy,Grigory V. Volchenkov,Ruwen Jou,Kai Kliiman,Olga V. Demikhova,J. Peter Cegielski +19 more
TL;DR: Less toxic and less expensive drugs and shorter treatment regimens are needed to improve the quality of life for patients in developing countries.